Prediction of treatment outcome in burning mouth syndrome patients using machine learning based on clinical data

The purpose of this study is to apply a machine learning approach to predict whether patients with burning mouth syndrome (BMS) respond to the initial approach and clonazepam therapy based on clinical data. Among the patients with the primary type of BMS who visited the clinic from 2006 to 2015, those treated with the initial approach of detailed explanation regarding home care instruction and use of oral topical lubricants, or who were prescribed clonazepam for a minimum of 1 month were included in this study. The clinical data and treatment outcomes were collected from medical records. Extreme Gradient-Boosted Decision Trees was used for machine learning algorithms to construct prediction models. Accuracy of the prediction models was evaluated and feature importance calculated. The accuracy of the prediction models for the initial approach and clonazepam therapy was 67.6% and 67.4%, respectively. Aggravating factors and psychological distress were important features in the prediction model for the initial approach, and intensity of symptoms before administration was the important feature in the prediction model for clonazepam therapy. In conclusion, the analysis of treatment outcomes in patients with BMS using a machine learning approach showed meaningful results of clinical applicability.

Case report of an infant with severe vitamin D deficiency rickets manifested as hypocalcemic seizures

Introduction. Hypocalcemic seizures are uncommon in the post-neonatal period. We report an infant with hypocalcemic seizures caused by severe deficiency of vitamin D. Case Outline. A five-month-old male infant was admitted to hospital in March 2013 with recurrent generalized afebrile seizures resistant to clonazepam therapy. At the clinical examination, the infant showed characteristic rachitic signs, so that after a blood sample was taken for laboratory testing, the infant was given infusion of 2 ml/kg of 10% of calcium gluconate at a rate of 0.5 ml/min. The treatment resulted in immediate termination of seizures and normalization of the consciousness of the infant. Blood sample analysis showed extremely low levels of free and total calcium (0.36/1.24 mmol/l) and 25(OH)D (<3 ng/ml), elevated alkaline phosphatase (878 U/l) and parathyroid hormone (283 pg/ml), and low calcium/creatinine ratio (mg/mg) in a portion of urine (0.03), while the levels of serum phosphorus, pH, total protein, albumin and creatinine were within the reference range. Wrist X-ray showed typical signs of rickets. In order to fully stabilize calcium homeostasis, along with 2,000 IU of vitamin D3 daily and standard cow?s milk formula, calcium gluconate (80 mg/kg daily) was given orally over a period of two weeks. The treatment resulted in complete stabilization of the infant?s condition and rapid improvement in laboratory, radiological and clinical findings of rickets. Conclusion. Generalized convulsions in the afebrile infant represent a serious and etiopathogenically very heterogeneous problem. Extremely rare, as in the case of our patient, it may be due to severe hypocalcemia caused by a deficiency of vitamin D.

Carbon dioxide induced panic attacks and short term clonazepam treatment: preliminary study

AIMS: 1. To verify the sensibility of panic patients to a mixture of 35% CO2 and 65% O2. 2. To determine if a ten days treatment with clonazepam attenuates the panic attacks induced by the inhalation of 35% carbon dioxide in panic disorder. METHOD: We randomly selected six panic disorder subjects, using the Structured Clinical Interview for DSM-IV. All subjects went double-blindly through an inhalation of 35% CO2 and compressed gas (atmospheric air) on two occasions. First, at baseline, when they were drug free. Second, after a 10 days clonazepam treatment. RESULTS: Neither at baseline nor after treatment any patient had a panic attack during compressed gas inhalation. At the first test five patients (83.3%) had a severe panic attack with high levels of subjective anxiety during carbon dioxide inhalation. After 9.6 (± 3.4) days of clonazepam treatment, only two (33.3%) patients experienced a mild panic attack. CONCLUSION: This pilot study suggests the efficacy of the short term clonazepam therapy in attenuating panic attacks and supports the usefulness of the 35% carbon dioxide challenge test as an analogue method for study the efficacy of anti-panic drugs. Further placebo-controlled studies to pharmacological treatment are warranted.

Buspirone and Sertraline in the Treatment of a Patient with Refractory Obsessive-Compulsive Disorder

Objective: To describe a hospitalized patient with refractory obsessive-compulsive disorder (OCD) and to briefly review the supporting literature. Case Summary: A 33-year-old man was admitted with a diagnosis of depression and OCD. Prior drug therapy included numerous medications, but none improved the OCD. Clonazepam therapy was initiated for treatment of anxiety and propranolol was begun to treat his headaches. Sertraline and buspirone were added sequentially to control the symptoms of depression and OCD. Subjective improvement was noted within a few weeks after the combination therapy was begun. Six and four weeks after starting sertraline and buspirone, respectively, the patient's symptoms remain improved. Discussion: Fluoxetine has been shown to be effective in the management of OCD. Sertraline, another selective serotonin-reuptake inhibitor, also looks promising for OCD therapy. Buspirone is a serotonin1A-receptor agonist, and theoretically could augment the effect of selective serotonin-reuptake inhibitors in the treatment of OCD. Conclusions: This patient's OCD symptoms responded to a combination of sertraline and buspirone therapy. It is difficult to confirm whether buspirone augmented the effects of sertraline in this patient. Clinical trials should be developed to determine whether these regimens are, in fact, beneficial in patients with refractory OCD.

High-Dose Lorazepam Therapy for Status Epilepticus in a Pediatric Patient

This report details the management of status epilepticus with high-dose lorazepam in a 14-year-old patient who was receiving oral clonazepam, ethosuximide, and phenobarbital for an intractable seizure disorder. Although respiratory depression is a frequently cited potential complication of therapy, it did not occur in this patient despite an extraordinarily high total dose of lorazepam, possibly because of tolerance associated with benzodiazepine-receptor down-regulation in this patient's chronic clonazepam therapy. Aggressive dosing of a benzodiazepine may be required for patients receiving chronic benzodiazepine therapy.